Managing regulatory submissions can feel like solving a big puzzle. With different rules for each country, lots of document formats, and tight deadlines, the process can get overwhelming. That’s where KnowledgeNET comes in—a powerful dossier software that makes regulatory submissions easier and faster. Why KnowledgeNET Is the Best Choice KnowledgeNET isn’t just software; it’s your […]
In the competitive world of pharmaceuticals, the ability to publish eCTD dossiers quickly and accurately can be the difference between securing a market lead and falling behind. Imagine being able to reduce your dossier publishing time by 60%! This isn’t just a dream; with the right tools, it’s entirely achievable. Enter KnowledgeNET, where innovation meets […]
Is your current eCTD viewer helping you manage regulatory submissions efficiently, or is it slowing you down? In the ever-evolving pharmaceutical landscape, having a reliable, intuitive tool is essential to keep up with complex submissions. But does your system give you the full picture? With KnowledgeNET’s eCTD Life Cycle Viewer, you gain more than just […]
What is the CEP 2.0? From the September 2023 this new CEP2.0 will be implemented. Manufacturer and the various organization want to know about what cep2.0 Cep2.0 is new look or the future cep. 1.What will change in the CEP2.0 As part of the implementation of the CEP 2.0, some changes are introduced, which affect […]
PRIME is a European Medicines Agency (EMA) initiative to increase assistance for the development of medicines that address an unmet medical need. Through PRIME, the Agency provides early and proactive support to drug developers to maximise the production of reliable data on a medicine’s benefits and risks and to allow accelerated assessment of drug applications. […]
The FDA is proposing to establish norms for a non-prescription medication with an additional condition for non-prescription use (ACNU). If implemented, the proposed rule would establish requirements for a non-prescription drug product with an ACNU that an applicant must implement to ensure appropriate self-selection or appropriate actual use, or both, by consumers who are not […]
“The format of the cover letter attachment can be customized by the applicant according to their convenience. The primary purpose of the cover letter attachment is to assist applicants in ensuring that they address relevant information in any cover letter they submit to the FDA for the submissions mentioned in this guidance. The cover letter […]
INDUSTRY CONSULTATION ON ELECTRONIC COMMON TECHNICAL DOCUMENT (eCTD) IMPLEMENTATION IN SINGAPORE Overview HSA is planning to introduce eCTD to enable full e-submissions thereby minimising the need for submitting documents using storage media such as CD/DVD ROMs. HSA is working with our appointed vendor to develop the eCTD system (ICH eCTD version 3.2.2) in Singapore. The […]
Holders of an active medical device establishment licence (MDEL) must apply to have their licence reviewed every year before April 1 in order to continue doing business. Those with a suspended MDEL are exempt from applying. An annual licence review (ALR) ensures that MDEL holders are: Adhering to regulatory requirements Maintaining their licence information up […]
According to FDA regulations, if an applicant wishes to pursue approval of its Abbreviated New Drug Application (ANDA), applicant must submit all materials required to fully address all shortcomings in the Complete Response Letter (CRL) within one year of the CRL’s issuance. The applicant must submit a request for an extension on or before the […]